var data={"title":"Histologic scoring systems for chronic liver disease","body":"<div id=\"topicContent\" class=\"utdArticleSection utdStyle\"><div id=\"topicTitle\">Histologic scoring systems for chronic liver disease</div><dl id=\"topicContributors\"><dt><span> </span>Author:</dt><dd><a href=\"https://www.uptodate.com/contents/histologic-scoring-systems-for-chronic-liver-disease/contributors\" class=\"contributor contributor_credentials\">Maria Isabel Fiel, MD, FAASLD</a></dd><dt><span> </span>Section Editor:</dt><dd><a href=\"https://www.uptodate.com/contents/histologic-scoring-systems-for-chronic-liver-disease/contributors\" class=\"contributor contributor_credentials\">Sanjiv Chopra, MD, MACP</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a href=\"https://www.uptodate.com/contents/histologic-scoring-systems-for-chronic-liver-disease/contributors\" class=\"contributor contributor_credentials\">Kristen M Robson, MD, MBA, FACG</a></dd></dl><p class=\"disclosureLink\"><a href=\"https://www.uptodate.com/contents/histologic-scoring-systems-for-chronic-liver-disease/contributor-disclosure\" class=\"contributor contributor_credentials\">Contributor Disclosures</a></p><div id=\"reviewProcess\"><span>All topics are updated as new evidence becomes available and our <a href=\"https://www.uptodate.com/home/editorial-policy\" target=\"_blank\" class=\"policy policy_editorialpolicy\">peer review process</a> is complete.</span></div><div id=\"literatureReviewDate\"><span class=\"emphasis\">Literature review current through:</span>&#160;Feb 2018.&#160;&#124;&#160;<span class=\"emphasis\">This topic last updated:</span>&#160;Jul 19, 2017.</div><div id=\"topicWhatsNewContainer\"></div><div id=\"topicText\"><p class=\"headingAnchor\" id=\"H23839870\"><span class=\"h1\">INTRODUCTION</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Histologic scoring systems for chronic liver disease are used to characterize and predict disease progression, to determine prognosis, to guide treatment strategies, and to provide standards in clinical trials. </p><p>This topic will review the major histologic scoring systems for chronic liver disease. The interpretation of liver biopsy specimens in general and methods to obtain liver biopsy specimens are discussed elsewhere. (See <a href=\"topic.htm?path=interpretation-of-liver-biopsy-specimens\" class=\"medical medical_review\">&quot;Interpretation of liver biopsy specimens&quot;</a> and <a href=\"topic.htm?path=approach-to-liver-biopsy\" class=\"medical medical_review\">&quot;Approach to liver biopsy&quot;</a> and <a href=\"topic.htm?path=transjugular-liver-biopsy\" class=\"medical medical_review\">&quot;Transjugular liver biopsy&quot;</a>.)</p><p class=\"headingAnchor\" id=\"H60230083\"><span class=\"h1\">LIMITATIONS OF LIVER BIOPSY</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>There are several limitations of liver biopsy for assessing liver disease, including: </p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Variable quality of liver biopsy specimens &ndash; Specimens shorter than 2 cm in length may be difficult to interpret. Larger caliber needles may yield better samples than fine needle biopsies [<a href=\"https://www.uptodate.com/contents/histologic-scoring-systems-for-chronic-liver-disease/abstract/1,2\" class=\"abstract_t\">1,2</a>]. As an example, small specimens may underestimate the degree of inflammatory activity and fibrosis in patients with viral hepatitis [<a href=\"https://www.uptodate.com/contents/histologic-scoring-systems-for-chronic-liver-disease/abstract/3\" class=\"abstract_t\">3</a>]. </p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Sampling variability &ndash; The assessment of liver histology is usually based on a percutaneous biopsy that samples a very small portion <span class=\"nowrap\">(1/50,000<sup>th</sup>)</span> of the liver [<a href=\"https://www.uptodate.com/contents/histologic-scoring-systems-for-chronic-liver-disease/abstract/4\" class=\"abstract_t\">4</a>]. Liver disease does not always affect the liver in a homogeneous pattern, leading to the possibility of sampling variability. The most common setting for sampling error is in a cirrhotic liver [<a href=\"https://www.uptodate.com/contents/histologic-scoring-systems-for-chronic-liver-disease/abstract/4\" class=\"abstract_t\">4</a>]. </p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Subjective assessment &ndash; This may lead to inter- and intraobserver variability or error [<a href=\"https://www.uptodate.com/contents/histologic-scoring-systems-for-chronic-liver-disease/abstract/5-7\" class=\"abstract_t\">5-7</a>]. </p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Fluctuating disease activity &ndash; Histologic changes obtained at a single point in time may not reflect overall disease activity, which may vary.</p><p/><p class=\"headingAnchor\" id=\"H23839876\"><span class=\"h1\">CHRONIC HEPATITIS</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>There are several scoring systems used to assess chronic hepatitis [<a href=\"https://www.uptodate.com/contents/histologic-scoring-systems-for-chronic-liver-disease/abstract/8-13\" class=\"abstract_t\">8-13</a>]. These systems help to assess prognosis and guide clinical management [<a href=\"https://www.uptodate.com/contents/histologic-scoring-systems-for-chronic-liver-disease/abstract/14\" class=\"abstract_t\">14</a>]. The scoring systems typically include descriptions of both necroinflammatory activity and the degree of fibrosis. An important difference among the scoring systems is in the staging of fibrosis. Scoring systems that include more stages for describing fibrosis are better able to document small changes in fibrosis over time. The Knodell score assigns patients to one of four stages, the METAVIR score to one of five, and the Ishak score to one of six.</p><p>Early scoring systems recognized two major histologic patterns, &quot;chronic persistent hepatitis&quot; and &quot;chronic aggressive hepatitis&quot; [<a href=\"https://www.uptodate.com/contents/histologic-scoring-systems-for-chronic-liver-disease/abstract/15\" class=\"abstract_t\">15</a>]. These patterns were associated with mild and more aggressive histologic categories of liver disease, respectively. Many other scoring systems were subsequently developed. Commonly used systems include:</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>The Knodell <span class=\"nowrap\">score/histology</span> activity index</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>The METAVIR score</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>The Ishak score (modified Knodell score)</p><p/><p>Other scoring systems include:</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>The Scheuer system</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>The Batts-Ludwig system</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Laennec staging system</p><p/><p>Most of the scoring systems for chronic hepatitis focus on viral etiologies, particularly hepatitis C virus (HCV) and hepatitis B virus infection. The same histologic scoring systems are used for autoimmune hepatitis. In rare instances, autoimmune hepatitis may be difficult to distinguish from chronic HCV [<a href=\"https://www.uptodate.com/contents/histologic-scoring-systems-for-chronic-liver-disease/abstract/16\" class=\"abstract_t\">16</a>].</p><p>The advent of highly effective, direct-acting antiviral medications for HCV has led to fewer liver biopsies being performed in order to grade and stage HCV because patients are often treated with anti-HCV medications regardless of the stage of fibrosis. (See <a href=\"topic.htm?path=patient-evaluation-and-selection-for-antiviral-therapy-for-chronic-hepatitis-c-virus-infection#H690483381\" class=\"medical medical_review\">&quot;Patient evaluation and selection for antiviral therapy for chronic hepatitis C virus infection&quot;, section on 'Role of liver biopsy'</a>.)</p><p class=\"headingAnchor\" id=\"H23839896\"><span class=\"h2\">Knodell score/histology activity index</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>The Knodell score (also known as the histology activity index) is a composite score that is based on histologic assessment of periportal <span class=\"nowrap\">and/or</span> bridging necrosis, intralobular degeneration and focal necrosis, portal inflammation, and fibrosis (<a href=\"image.htm?imageKey=GAST%2F56831\" class=\"graphic graphic_table graphicRef56831 \">table 1</a> and <a href=\"image.htm?imageKey=GAST%2F97253%7EGAST%2F97269%7EGAST%2F98079%7EGAST%2F97270%7EGAST%2F97271\" class=\"graphic graphic_picture graphicRef97253 graphicRef97269 graphicRef98079 graphicRef97270 graphicRef97271 \">picture 1A-E</a>). The score ranges from 0 to 22, with higher scores representing more advanced disease [<a href=\"https://www.uptodate.com/contents/histologic-scoring-systems-for-chronic-liver-disease/abstract/8\" class=\"abstract_t\">8</a>]. A decrease in the Knodell score corresponds with histologic improvement. </p><p>The Knodell score is frequently used in trials of treatments for chronic hepatitis, particularly HCV. The score is used to assure that baseline histologic features in treatment groups are equally matched and to assess histologic changes after therapy.</p><p>A limitation of the Knodell score is that it combines inflammation and fibrosis to arrive at one composite score, so it is relatively insensitive to changes in fibrosis. This is important because it is fibrosis, and not inflammation per se, that leads to many of the sequelae of chronic liver disease. In addition, patients may have the same Knodell score despite having markedly different degrees of fibrosis. </p><p>The Knodell score is also associated with high inter- and intraobserver variability. In a study of 10 pathologists using a cohort of 30 liver biopsy specimens from patients who had documented HCV infection, interobserver correlation for the three inflammatory components of the Knodell score was relatively poor (with kappa coefficients ranging from 0.25 to 0.46 [a perfect coefficient being 1.00]) [<a href=\"https://www.uptodate.com/contents/histologic-scoring-systems-for-chronic-liver-disease/abstract/9\" class=\"abstract_t\">9</a>]. The interobserver correlation for the overall score was also relatively poor, ranging from 0.48 to 0.57. Only the fibrosis score had good reliability, with a kappa coefficient of approximately 0.80. Similar results were found for intraobserver reliability.</p><p class=\"headingAnchor\" id=\"H23839890\"><span class=\"h2\">METAVIR score</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>The METAVIR score is a semiquantitative classification system that consists of an activity score and a fibrosis score (represented by a two letter and two number coding system) (<a href=\"image.htm?imageKey=GAST%2F98097\" class=\"graphic graphic_table graphicRef98097 \">table 2</a> and <a href=\"image.htm?imageKey=GAST%2F97272%7EGAST%2F97279%7EGAST%2F97281%7EGAST%2F97280\" class=\"graphic graphic_picture graphicRef97272 graphicRef97279 graphicRef97281 graphicRef97280 \">picture 2A-D</a>) [<a href=\"https://www.uptodate.com/contents/histologic-scoring-systems-for-chronic-liver-disease/abstract/9,10\" class=\"abstract_t\">9,10</a>]:</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>The activity score is graded according to the intensity of necroinflammatory lesions (A0 = no activity, A1 = mild activity, A2 = moderate activity, A3 = severe activity).</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>The fibrosis score is assessed on a five-point scale (F0 = no fibrosis, F1 = portal fibrosis without septa, F2 = few septa, F3 = numerous septa without cirrhosis, F4 = cirrhosis).</p><p/><p>In contrast to the Knodell score, which was designed as a generic scoring system for chronic hepatitis, the METAVIR score was specifically designed and validated for patients with HCV [<a href=\"https://www.uptodate.com/contents/histologic-scoring-systems-for-chronic-liver-disease/abstract/9\" class=\"abstract_t\">9</a>]. The inter- and intraobserver reliability of the activity and fibrosis scores of the METAVIR system are similar to the Knodell score. A study found that the interobserver agreement of the METAVIR score depends highly upon the experience of the hepatopathologist [<a href=\"https://www.uptodate.com/contents/histologic-scoring-systems-for-chronic-liver-disease/abstract/5\" class=\"abstract_t\">5</a>]. Agreement was influenced more heavily by the interpreter's experience than by features of the specimen itself, such as its length. However, a separate study evaluating the fibrosis and activity scores in specimens of various lengths suggested that the length of the biopsy is also important [<a href=\"https://www.uptodate.com/contents/histologic-scoring-systems-for-chronic-liver-disease/abstract/2\" class=\"abstract_t\">2</a>].</p><p class=\"headingAnchor\" id=\"H23839902\"><span class=\"h2\">Ishak score (modified Knodell score)</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>The Ishak score is a modification of the Knodell score that includes six stages of fibrosis (<a href=\"image.htm?imageKey=GAST%2F98101\" class=\"graphic graphic_table graphicRef98101 \">table 3</a> and <a href=\"image.htm?imageKey=GAST%2F97283%7EGAST%2F97296%7EGAST%2F97297%7EGAST%2F97298%7EGAST%2F97299%7EGAST%2F97300%7EGAST%2F97301\" class=\"graphic graphic_picture graphicRef97283 graphicRef97296 graphicRef97297 graphicRef97298 graphicRef97299 graphicRef97300 graphicRef97301 \">picture 3A-G</a>) [<a href=\"https://www.uptodate.com/contents/histologic-scoring-systems-for-chronic-liver-disease/abstract/11\" class=\"abstract_t\">11</a>]. This permits documentation of small changes in fibrosis compared with the standard Knodell fibrosis score, which has only four stages. Like the METAVIR score, the grades for necroinflammation (<a href=\"image.htm?imageKey=GAST%2F97282\" class=\"graphic graphic_picture graphicRef97282 \">picture 4</a>) are categorized separately from the stage of fibrosis (<a href=\"image.htm?imageKey=GAST%2F98099\" class=\"graphic graphic_table graphicRef98099 \">table 4</a>).</p><p>This staging system has become widely used in clinical trials because of its ability to detect mild changes in fibrosis.</p><p class=\"headingAnchor\" id=\"H23839909\"><span class=\"h2\">Scheuer system</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>The Scheuer system is a simple scoring system that separates necroinflammation from fibrosis [<a href=\"https://www.uptodate.com/contents/histologic-scoring-systems-for-chronic-liver-disease/abstract/12\" class=\"abstract_t\">12</a>]. Histologic findings of portal inflammation, interface hepatitis, and lobular inflammation are each assigned a score of 0 to 4 (<a href=\"image.htm?imageKey=GAST%2F98102\" class=\"graphic graphic_table graphicRef98102 \">table 5</a>). A separate score (0 to 4) is assigned to the stage of fibrosis (<a href=\"image.htm?imageKey=GAST%2F97302%7EGAST%2F97303%7EGAST%2F97304%7EGAST%2F97305\" class=\"graphic graphic_picture graphicRef97302 graphicRef97303 graphicRef97304 graphicRef97305 \">picture 5A-D</a>).</p><p class=\"headingAnchor\" id=\"H23841513\"><span class=\"h2\">Batts-Ludwig system (modified Scheuer system)</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>This system is also known as the modified Scheuer system [<a href=\"https://www.uptodate.com/contents/histologic-scoring-systems-for-chronic-liver-disease/abstract/13\" class=\"abstract_t\">13</a>]. In the original description, diagrams of the different grades and stages of chronic hepatitis were depicted. Either a semiquantitative numeric value or a descriptive term can be used, depending on local preferences (<a href=\"image.htm?imageKey=GAST%2F98103\" class=\"graphic graphic_table graphicRef98103 \">table 6</a>).</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Necroinflammatory activity (grade) is based on lymphocytic piecemeal necrosis (interface hepatitis) and lobular necroinflammatory activity (<a href=\"image.htm?imageKey=GAST%2F97370%7EGAST%2F97371%7EGAST%2F97373%7EGAST%2F97374%7EGAST%2F97375\" class=\"graphic graphic_picture graphicRef97370 graphicRef97371 graphicRef97373 graphicRef97374 graphicRef97375 \">picture 6A-E</a>) </p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>The stage refers to the degree of fibrosis (<a href=\"image.htm?imageKey=GAST%2F97376\" class=\"graphic graphic_picture graphicRef97376 \">picture 7</a>) </p><p/><p>This grading system is applicable to both chronic viral hepatitis (<a href=\"image.htm?imageKey=GAST%2F97377\" class=\"graphic graphic_picture graphicRef97377 \">picture 8</a>) and autoimmune hepatitis. This system is more useful for assessing an individual patient's liver biopsy for clinical care than it is for therapeutic trials.</p><p class=\"headingAnchor\" id=\"H23841551\"><span class=\"h2\">Laennec staging system</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>This system is a modification of the METAVIR F4 (cirrhosis) fibrosis category and was developed based on the observation that cirrhosis may have different degrees of severity that influence the disease's natural history, clinical behavior, and prognosis [<a href=\"https://www.uptodate.com/contents/histologic-scoring-systems-for-chronic-liver-disease/abstract/17\" class=\"abstract_t\">17</a>]. The system subdivides F4 cirrhosis into three categories based on the width and number of fibrous septa, as well as the size of the nodules, with more emphasis and consideration given to micronodules (<a href=\"image.htm?imageKey=GAST%2F97379%7EGAST%2F97380%7EGAST%2F97381\" class=\"graphic graphic_picture graphicRef97379 graphicRef97380 graphicRef97381 \">picture 9A-C</a> and <a href=\"image.htm?imageKey=GAST%2F98104\" class=\"graphic graphic_table graphicRef98104 \">table 7</a>). </p><p>Positive correlation between the Laennec stage and hepatic venous pressure gradient was established by one study [<a href=\"https://www.uptodate.com/contents/histologic-scoring-systems-for-chronic-liver-disease/abstract/18\" class=\"abstract_t\">18</a>]. Another study showed that a higher Laennec cirrhosis stage is associated with a higher risk for the occurrence of a liver-related event such as decompensation, hepatocellular carcinoma, or liver-related death [<a href=\"https://www.uptodate.com/contents/histologic-scoring-systems-for-chronic-liver-disease/abstract/19\" class=\"abstract_t\">19</a>]. (See <a href=\"topic.htm?path=portal-hypertension-in-adults#H72827684\" class=\"medical medical_review\">&quot;Portal hypertension in adults&quot;, section on 'Hepatic venous pressure gradient'</a>.)</p><p class=\"headingAnchor\" id=\"H60229745\"><span class=\"h1\">DISEASE-SPECIFIC SCORING SYSTEMS</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Disease-specific scoring systems are also available, including scoring systems for nonalcoholic fatty liver disease (NAFLD), alcoholic hepatitis, primary biliary cholangitis, and primary sclerosing cholangitis (PSC). However, it is not uncommon to encounter two or more concurrent diseases in a liver biopsy specimen, and no scoring systems are available that specifically address these situations.</p><p class=\"headingAnchor\" id=\"H2349826112\"><span class=\"h2\">Nonalcoholic fatty liver disease</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>NAFLD is subdivided into nonalcoholic fatty liver (NAFL) and nonalcoholic steatohepatitis (NASH) although these are considered to be part of a spectrum. In NAFL, hepatic steatosis is present without evidence of hepatocyte ballooning degeneration or significant inflammation, whereas in NASH, hepatic steatosis is associated with hepatocyte ballooning degeneration and hepatic inflammation that may be histologically indistinguishable from alcoholic steatohepatitis [<a href=\"https://www.uptodate.com/contents/histologic-scoring-systems-for-chronic-liver-disease/abstract/20\" class=\"abstract_t\">20</a>]. The clinical features and diagnosis of NAFLD are discussed separately (See <a href=\"topic.htm?path=epidemiology-clinical-features-and-diagnosis-of-nonalcoholic-fatty-liver-disease-in-adults#H7\" class=\"medical medical_review\">&quot;Epidemiology, clinical features, and diagnosis of nonalcoholic fatty liver disease in adults&quot;, section on 'Clinical manifestations'</a> and <a href=\"topic.htm?path=epidemiology-clinical-features-and-diagnosis-of-nonalcoholic-fatty-liver-disease-in-adults#H8\" class=\"medical medical_review\">&quot;Epidemiology, clinical features, and diagnosis of nonalcoholic fatty liver disease in adults&quot;, section on 'Diagnosis'</a>.)</p><p>Although liver biopsy can confirm the diagnosis of NASH, grade disease severity and accurately stage fibrosis, noninvasive methods for evaluating NASH are being studied. (See <a href=\"topic.htm?path=epidemiology-clinical-features-and-diagnosis-of-nonalcoholic-fatty-liver-disease-in-adults\" class=\"medical medical_review\">&quot;Epidemiology, clinical features, and diagnosis of nonalcoholic fatty liver disease in adults&quot;</a>.)</p><p>There are three scoring systems for NAFLD:</p><p class=\"headingAnchor\" id=\"H2031372065\"><span class=\"h3\">Nonalcoholic fatty liver activity score</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>The nonalcoholic fatty liver activity score (NAS) (<a href=\"image.htm?imageKey=GAST%2F97419%7EGAST%2F97420%7EGAST%2F97421\" class=\"graphic graphic_picture graphicRef97419 graphicRef97420 graphicRef97421 \">picture 10A-C</a> and <a href=\"image.htm?imageKey=GAST%2F98135\" class=\"graphic graphic_table graphicRef98135 \">table 8</a>) is a system of histologic evaluation that includes the full spectrum of nonalcoholic fatty liver disease and can assess changes following therapy in both adult and pediatric patients [<a href=\"https://www.uptodate.com/contents/histologic-scoring-systems-for-chronic-liver-disease/abstract/20\" class=\"abstract_t\">20</a>]. The NAS is the unweighted sum of scores for:</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Steatosis </p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Lobular inflammation </p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Ballooning </p><p/><p>The NAS ranges from 0 to 8 [<a href=\"https://www.uptodate.com/contents/histologic-scoring-systems-for-chronic-liver-disease/abstract/20\" class=\"abstract_t\">20</a>]. Fibrosis is not included in the NAS. In the study that derived the NAS, scores of 0 to 2 occurred in cases largely considered not diagnostic of NASH; scores of 3 to 4 were evenly divided among those considered not diagnostic, borderline, or positive for NASH; and scores of 5 to 8 occurred in cases that were largely considered diagnostic of NASH [<a href=\"https://www.uptodate.com/contents/histologic-scoring-systems-for-chronic-liver-disease/abstract/20\" class=\"abstract_t\">20</a>]. In practice, NAS is used to grade the activity of NASH, rather than to make a histologic diagnosis of NASH [<a href=\"https://www.uptodate.com/contents/histologic-scoring-systems-for-chronic-liver-disease/abstract/21\" class=\"abstract_t\">21</a>]. </p><p class=\"headingAnchor\" id=\"H47275257\"><span class=\"h3\">Steatosis, activity and fibrosis system</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>With the steatosis, activity, and fibrosis (SAF) system, a diagnosis of NASH can be established [<a href=\"https://www.uptodate.com/contents/histologic-scoring-systems-for-chronic-liver-disease/abstract/22\" class=\"abstract_t\">22</a>]. Steatosis, activity, and fibrosis are separately assessed and the sum of the scores for lobular inflammation and ballooning define activity (range, 0 to 4). Patients with activity score of 2 or greater are diagnosed with NASH.</p><p class=\"headingAnchor\" id=\"H497091710\"><span class=\"h3\">Fatty liver inhibition and progression</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>The fatty liver inhibition of progression (FLIP) pathology consortium created a histologic algorithm (FLIP algorithm) based on the SAF scoring system to limit interobserver variation among pathologists. [<a href=\"https://www.uptodate.com/contents/histologic-scoring-systems-for-chronic-liver-disease/abstract/23\" class=\"abstract_t\">23</a>].</p><p class=\"headingAnchor\" id=\"H1366946536\"><span class=\"h2\">Alcoholic liver disease and alcoholic hepatitis</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Histologic grading and staging systems for alcoholic liver disease have not been validated, and scoring systems developed for NAFLD and NASH are being used for alcohol-related liver disease. Histologically, alcoholic steatohepatitis (ASH) is similar to NASH, and often these two entities are indistinguishable from each other on biopsy. Some features may favor a diagnosis of alcoholic hepatitis, though they are not specific to alcoholic hepatitis. These features include cholestasis, numerous well-formed Mallory-Denk bodies, neutrophilic satellitosis, and central hyaline sclerosis [<a href=\"https://www.uptodate.com/contents/histologic-scoring-systems-for-chronic-liver-disease/abstract/24\" class=\"abstract_t\">24</a>]. Mallory-Denk bodies are almost always seen with ballooned hepatocytes and are not as well-formed compared with those found in NASH. (See <a href=\"topic.htm?path=interpretation-of-liver-biopsy-specimens#H1763618216\" class=\"medical medical_review\">&quot;Interpretation of liver biopsy specimens&quot;, section on 'Alcoholic steatohepatitis'</a>.)</p><p>One study proposed a semiquantitative histologic scoring system that relates to the prognosis in patients with alcoholic hepatitis (<a href=\"image.htm?imageKey=GAST%2F98136\" class=\"graphic graphic_table graphicRef98136 \">table 9</a>) [<a href=\"https://www.uptodate.com/contents/histologic-scoring-systems-for-chronic-liver-disease/abstract/25\" class=\"abstract_t\">25</a>]. Based on multivariate regression analysis, the group came up with a scoring system that utilizes four histologic features, scoring each feature individually (degree of fibrosis, degree of neutrophil infiltration, type of bilirubinostasis, and presence of megamitochondria) (<a href=\"image.htm?imageKey=GAST%2F97422%7EGAST%2F97423%7EGAST%2F97454%7EGAST%2F97455\" class=\"graphic graphic_picture graphicRef97422 graphicRef97423 graphicRef97454 graphicRef97455 \">picture 11A-D</a>). The risk of death is positively associated with the stage of fibrosis and degree of bilirubinostasis and is negatively correlated with neutrophil infiltration and the presence of megamitochondria (ie, mild neutrophil infiltration or the absence of megamitochondria is associated with a worse prognosis). The individual scores are combined to reach a final score (maximum score of 9). The investigators found that a low score (0 to 3) was associated with a 90-day mortality of 3 percent, whereas moderate (4 to 5 points) and high (6 to 9 points) scores were associated with higher mortality rates (19 and 51 percent, respectively).</p><p class=\"headingAnchor\" id=\"H143941062\"><span class=\"h2\">Primary biliary cholangitis</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Primary biliary cholangitis (PBC) is classically staged using either the Scheuer system for PBC (<a href=\"image.htm?imageKey=GAST%2F98137\" class=\"graphic graphic_table graphicRef98137 \">table 10</a> and <a href=\"image.htm?imageKey=GAST%2F97457%7EGAST%2F97458%7EGAST%2F97459%7EGAST%2F97460\" class=\"graphic graphic_picture graphicRef97457 graphicRef97458 graphicRef97459 graphicRef97460 \">picture 12A-D</a>) or a system proposed by Ludwig (<a href=\"image.htm?imageKey=GAST%2F98138\" class=\"graphic graphic_table graphicRef98138 \">table 11</a>) that differs from the Batts-Ludwig system described above [<a href=\"https://www.uptodate.com/contents/histologic-scoring-systems-for-chronic-liver-disease/abstract/26-28\" class=\"abstract_t\">26-28</a>] (See <a href=\"topic.htm?path=clinical-manifestations-diagnosis-and-prognosis-of-primary-biliary-cholangitis-primary-biliary-cirrhosis#H58140687\" class=\"medical medical_review\">&quot;Clinical manifestations, diagnosis, and prognosis of primary biliary cholangitis (primary biliary cirrhosis)&quot;, section on 'Liver biopsy'</a>.). </p><p>Because these scoring systems do not include the degree of portal lymphoplasmacytic inflammation that may be found in association with PBC, a histologic staging and grading system specifically for PBC has been proposed. In the Nakanuma system, histologic stage is based on three features: fibrosis, bile duct loss, and deposition of copper-associated protein on orcein stain.</p><p>The final Nakanuma stage is obtained from the total score of the three features of histologic stage [<a href=\"https://www.uptodate.com/contents/histologic-scoring-systems-for-chronic-liver-disease/abstract/29,30\" class=\"abstract_t\">29,30</a>] :</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Stage I = no or minimal progression (score of 0)</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Stage II = mild progression (score of 1 to 3)</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Stage III = moderate progression (score of 4 to 6)</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Stage IV = advanced progression (score of 7 to 9).</p><p/><p>The Nakanuma scoring system for histologic grade includes degree of cholangitis activity (score 0 to 3), and hepatitis activity (score 0 to 3) [<a href=\"https://www.uptodate.com/contents/histologic-scoring-systems-for-chronic-liver-disease/abstract/29\" class=\"abstract_t\">29</a>]. Additional validation studies are needed before this histologic scoring system can be employed in clinical practice [<a href=\"https://www.uptodate.com/contents/histologic-scoring-systems-for-chronic-liver-disease/abstract/31\" class=\"abstract_t\">31</a>].</p><p class=\"headingAnchor\" id=\"H1929080470\"><span class=\"h2\">Primary sclerosing cholangitis</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>It is uncommon to perform a liver biopsy to make a diagnosis of PSC, but if a biopsy is performed, the Ludwig histologic staging system used for PSC is as follows [<a href=\"https://www.uptodate.com/contents/histologic-scoring-systems-for-chronic-liver-disease/abstract/32-35\" class=\"abstract_t\">32-35</a>] (<a href=\"image.htm?imageKey=GAST%2F97461%7EGAST%2F97462%7EGAST%2F97486%7EGAST%2F97487\" class=\"graphic graphic_picture graphicRef97461 graphicRef97462 graphicRef97486 graphicRef97487 \">picture 13A-D</a> and <a href=\"image.htm?imageKey=GAST%2F98139\" class=\"graphic graphic_table graphicRef98139 \">table 12</a>) (see <a href=\"topic.htm?path=primary-sclerosing-cholangitis-in-adults-clinical-manifestations-and-diagnosis#H57939016\" class=\"medical medical_review\">&quot;Primary sclerosing cholangitis in adults: Clinical manifestations and diagnosis&quot;, section on 'Liver biopsy'</a>):</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Stage 1: The portal tracts are expanded by edema and fibrosis, and there is a mononuclear cell infiltration with some interface hepatitis and damage to isolated bile ducts. Proliferation of bile ductules with mononuclear and polymorphonuclear cells may also be present, although the inflammation is usually less dense than in PBC.</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Stage 2: Expansion of portal triads with fibrosis extending into the surrounding parenchyma.</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Stage 3: Bridging fibrosis.</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Stage 4: Cirrhosis.</p><p>In a study that evaluated three scoring systems (Ishak, Ludwig and Nakanuma) to determine the applicability and prognostic value of scores in a group of PSC patients, interobserver agreement was moderate to substantial in all three systems [<a href=\"https://www.uptodate.com/contents/histologic-scoring-systems-for-chronic-liver-disease/abstract/11,27,29,30\" class=\"abstract_t\">11,27,29,30</a>]. All three staging systems were also shown to be independent predictors of both liver transplantation and complications related to cirrhosis, but they found that the Nakanuma staging system was independently associated with the endpoint of PSC-related death and liver transplantation (HR 2.14, 95%CI 1.22-3.77). </p><p class=\"headingAnchor\" id=\"H60230201\"><span class=\"h2\">Autoimmune hepatitis</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>The histologic grading systems for chronic hepatitis are also applied to autoimmune hepatitis because, as of yet, there is no formal histological classification system available specifically for autoimmune hepatitis. (See <a href=\"#H23839876\" class=\"local\">'Chronic hepatitis'</a> above.) </p><p class=\"headingAnchor\" id=\"H23841634\"><span class=\"h1\">SUMMARY</span></p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Histologic scoring systems for chronic liver disease are used to characterize and predict disease progression, to determine prognosis, to guide treatment strategies, and to provide standards in clinical trials. </p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Commonly used scoring systems for chronic hepatitis include:</p><p/><p class=\"bulletIndent2\"><span class=\"glyph\">&#8226;</span>The Knodell <span class=\"nowrap\">score/histology</span> activity index (<a href=\"image.htm?imageKey=GAST%2F56831\" class=\"graphic graphic_table graphicRef56831 \">table 1</a>) (see <a href=\"#H23839896\" class=\"local\">'Knodell score/histology activity index'</a> above).</p><p class=\"bulletIndent2\"><span class=\"glyph\">&#8226;</span>The METAVIR score (<a href=\"image.htm?imageKey=GAST%2F98097\" class=\"graphic graphic_table graphicRef98097 \">table 2</a>) (see <a href=\"#H23839890\" class=\"local\">'METAVIR score'</a> above).</p><p class=\"bulletIndent2\"><span class=\"glyph\">&#8226;</span>The Ishak score (modified Knodell score) (<a href=\"image.htm?imageKey=GAST%2F98101\" class=\"graphic graphic_table graphicRef98101 \">table 3</a> and <a href=\"image.htm?imageKey=GAST%2F98099\" class=\"graphic graphic_table graphicRef98099 \">table 4</a>) (see <a href=\"#H23839902\" class=\"local\">'Ishak score (modified Knodell score)'</a> above).</p><p/><p class=\"bulletIndent1\">These scoring systems include descriptions of both necroinflammatory activity and the degree of fibrosis. An important difference among the scoring systems is in the staging of fibrosis. Scoring systems that include more stages for describing fibrosis are better able to document small changes in fibrosis over time. The Knodell score assigns patients to one of four stages, the METAVIR score to one of five, and the Ishak score to one of six.</p><p/><p class=\"bulletIndent1\">Other scoring systems include:</p><p/><p class=\"bulletIndent2\"><span class=\"glyph\">&#8226;</span>The Scheuer system (<a href=\"image.htm?imageKey=GAST%2F98102\" class=\"graphic graphic_table graphicRef98102 \">table 5</a>) (see <a href=\"#H23839909\" class=\"local\">'Scheuer system'</a> above)</p><p class=\"bulletIndent2\"><span class=\"glyph\">&#8226;</span>The Batts-Ludwig system (<a href=\"image.htm?imageKey=GAST%2F98103\" class=\"graphic graphic_table graphicRef98103 \">table 6</a>) (see <a href=\"#H23841513\" class=\"local\">'Batts-Ludwig system (modified Scheuer system)'</a> above)</p><p class=\"bulletIndent2\"><span class=\"glyph\">&#8226;</span>Laennec staging system (<a href=\"image.htm?imageKey=GAST%2F98104\" class=\"graphic graphic_table graphicRef98104 \">table 7</a>) (see <a href=\"#H23841551\" class=\"local\">'Laennec staging system'</a> above)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Scoring systems also exist for specific liver diseases, including:</p><p/><p class=\"bulletIndent2\"><span class=\"glyph\">&#8226;</span>Nonalcoholic fatty liver disease (<a href=\"image.htm?imageKey=GAST%2F98135\" class=\"graphic graphic_table graphicRef98135 \">table 8</a> and <a href=\"image.htm?imageKey=GAST%2F98105\" class=\"graphic graphic_table graphicRef98105 \">table 13</a>) (see <a href=\"#H2349826112\" class=\"local\">'Nonalcoholic fatty liver disease'</a> above).</p><p class=\"bulletIndent2\"><span class=\"glyph\">&#8226;</span>Alcoholic hepatitis (<a href=\"image.htm?imageKey=GAST%2F98136\" class=\"graphic graphic_table graphicRef98136 \">table 9</a>) (see <a href=\"#H1366946536\" class=\"local\">'Alcoholic liver disease and alcoholic hepatitis'</a> above).</p><p class=\"bulletIndent2\"><span class=\"glyph\">&#8226;</span>Primary biliary cirrhosis (<a href=\"image.htm?imageKey=GAST%2F98137\" class=\"graphic graphic_table graphicRef98137 \">table 10</a> and <a href=\"image.htm?imageKey=GAST%2F98138\" class=\"graphic graphic_table graphicRef98138 \">table 11</a>) (see <a href=\"#H143941062\" class=\"local\">'Primary biliary cholangitis'</a> above).</p><p class=\"bulletIndent2\"><span class=\"glyph\">&#8226;</span>Primary sclerosing cholangitis (<a href=\"image.htm?imageKey=GAST%2F98139\" class=\"graphic graphic_table graphicRef98139 \">table 12</a>) (see <a href=\"#H1929080470\" class=\"local\">'Primary sclerosing cholangitis'</a> above).</p></div><div id=\"topicAgreement\">Use of UpToDate is subject to the <a href=\"https://www.uptodate.com/legal/license\" class=\"licenseLink\" id=\"sla_in_page\">Subscription and License Agreement</a>.</div><div id=\"references\" class=\"headingAnchor\"><h1>REFERENCES</h1><ol id=\"reference\"><li><a href=\"https://www.uptodate.com/contents/histologic-scoring-systems-for-chronic-liver-disease/abstract/1\" class=\"nounderline abstract_t\">Colloredo G, Guido M, Sonzogni A, Leandro G. Impact of liver biopsy size on histological evaluation of chronic viral hepatitis: the smaller the sample, the milder the disease. J Hepatol 2003; 39:239.</a></li><li><a href=\"https://www.uptodate.com/contents/histologic-scoring-systems-for-chronic-liver-disease/abstract/2\" class=\"nounderline abstract_t\">Schiano TD, Azeem S, Bodian CA, et al. Importance of specimen size in accurate needle liver biopsy evaluation of patients with chronic hepatitis C. Clin Gastroenterol Hepatol 2005; 3:930.</a></li><li><a href=\"https://www.uptodate.com/contents/histologic-scoring-systems-for-chronic-liver-disease/abstract/3\" class=\"nounderline abstract_t\">Bedossa P, Darg&egrave;re D, Paradis V. Sampling variability of liver fibrosis in chronic hepatitis C. Hepatology 2003; 38:1449.</a></li><li><a href=\"https://www.uptodate.com/contents/histologic-scoring-systems-for-chronic-liver-disease/abstract/4\" class=\"nounderline abstract_t\">Sumida Y, Nakajima A, Itoh Y. Limitations of liver biopsy and non-invasive diagnostic tests for the diagnosis of nonalcoholic fatty liver disease/nonalcoholic steatohepatitis. World J Gastroenterol 2014; 20:475.</a></li><li><a href=\"https://www.uptodate.com/contents/histologic-scoring-systems-for-chronic-liver-disease/abstract/5\" class=\"nounderline abstract_t\">Rousselet MC, Michalak S, Dupr&eacute; F, et al. Sources of variability in histological scoring of chronic viral hepatitis. Hepatology 2005; 41:257.</a></li><li><a href=\"https://www.uptodate.com/contents/histologic-scoring-systems-for-chronic-liver-disease/abstract/6\" class=\"nounderline abstract_t\">Soloway RD, Baggenstoss AH, Schoenfield LJ, Summerskill WH. Observer error and sampling variability tested in evaluation of hepatitis and cirrhosis by liver biopsy. Am J Dig Dis 1971; 16:1082.</a></li><li><a href=\"https://www.uptodate.com/contents/histologic-scoring-systems-for-chronic-liver-disease/abstract/7\" class=\"nounderline abstract_t\">Goldin RD, Goldin JG, Burt AD, et al. Intra-observer and inter-observer variation in the histopathological assessment of chronic viral hepatitis. J Hepatol 1996; 25:649.</a></li><li><a href=\"https://www.uptodate.com/contents/histologic-scoring-systems-for-chronic-liver-disease/abstract/8\" class=\"nounderline abstract_t\">Knodell RG, Ishak KG, Black WC, et al. Formulation and application of a numerical scoring system for assessing histological activity in asymptomatic chronic active hepatitis. Hepatology 1981; 1:431.</a></li><li><a href=\"https://www.uptodate.com/contents/histologic-scoring-systems-for-chronic-liver-disease/abstract/9\" class=\"nounderline abstract_t\">Intraobserver and interobserver variations in liver biopsy interpretation in patients with chronic hepatitis C. The French METAVIR Cooperative Study Group. Hepatology 1994; 20:15.</a></li><li><a href=\"https://www.uptodate.com/contents/histologic-scoring-systems-for-chronic-liver-disease/abstract/10\" class=\"nounderline abstract_t\">Bedossa P, Poynard T. An algorithm for the grading of activity in chronic hepatitis C. The METAVIR Cooperative Study Group. Hepatology 1996; 24:289.</a></li><li><a href=\"https://www.uptodate.com/contents/histologic-scoring-systems-for-chronic-liver-disease/abstract/11\" class=\"nounderline abstract_t\">Ishak K, Baptista A, Bianchi L, et al. Histological grading and staging of chronic hepatitis. J Hepatol 1995; 22:696.</a></li><li><a href=\"https://www.uptodate.com/contents/histologic-scoring-systems-for-chronic-liver-disease/abstract/12\" class=\"nounderline abstract_t\">Scheuer PJ. Classification of chronic viral hepatitis: a need for reassessment. J Hepatol 1991; 13:372.</a></li><li><a href=\"https://www.uptodate.com/contents/histologic-scoring-systems-for-chronic-liver-disease/abstract/13\" class=\"nounderline abstract_t\">Batts KP, Ludwig J. Chronic hepatitis. An update on terminology and reporting. Am J Surg Pathol 1995; 19:1409.</a></li><li><a href=\"https://www.uptodate.com/contents/histologic-scoring-systems-for-chronic-liver-disease/abstract/14\" class=\"nounderline abstract_t\">Fiel MI. Pathology of chronic hepatitis B and chronic hepatitis C. Clin Liver Dis 2010; 14:555.</a></li><li><a href=\"https://www.uptodate.com/contents/histologic-scoring-systems-for-chronic-liver-disease/abstract/15\" class=\"nounderline abstract_t\">De Groote J, Desmet VJ, Gedigk P, et al. A classification of chronic hepatitis. Lancet 1968; 2:626.</a></li><li><a href=\"https://www.uptodate.com/contents/histologic-scoring-systems-for-chronic-liver-disease/abstract/16\" class=\"nounderline abstract_t\">Bach N, Thung SN, Schaffner F. The histological features of chronic hepatitis C and autoimmune chronic hepatitis: a comparative analysis. Hepatology 1992; 15:572.</a></li><li><a href=\"https://www.uptodate.com/contents/histologic-scoring-systems-for-chronic-liver-disease/abstract/17\" class=\"nounderline abstract_t\">Kutami R, Girgrah N, Wanless I, et al. The Laennec grading system for assessment of hepatic fibrosis: validation by correlation with wedged hepatic vein pressure and clinical features. Hepatology 2000; 32:407A.</a></li><li><a href=\"https://www.uptodate.com/contents/histologic-scoring-systems-for-chronic-liver-disease/abstract/18\" class=\"nounderline abstract_t\">Rastogi A, Maiwall R, Bihari C, et al. Cirrhosis histology and Laennec staging system correlate with high portal pressure. Histopathology 2013; 62:731.</a></li><li><a href=\"https://www.uptodate.com/contents/histologic-scoring-systems-for-chronic-liver-disease/abstract/19\" class=\"nounderline abstract_t\">Kim SU, Oh HJ, Wanless IR, et al. The Laennec staging system for histological sub-classification of cirrhosis is useful for stratification of prognosis in patients with liver cirrhosis. J Hepatol 2012; 57:556.</a></li><li><a href=\"https://www.uptodate.com/contents/histologic-scoring-systems-for-chronic-liver-disease/abstract/20\" class=\"nounderline abstract_t\">Kleiner DE, Brunt EM, Van Natta M, et al. Design and validation of a histological scoring system for nonalcoholic fatty liver disease. Hepatology 2005; 41:1313.</a></li><li><a href=\"https://www.uptodate.com/contents/histologic-scoring-systems-for-chronic-liver-disease/abstract/21\" class=\"nounderline abstract_t\">Brunt EM, Kleiner DE, Wilson LA, et al. Nonalcoholic fatty liver disease (NAFLD) activity score and the histopathologic diagnosis in NAFLD: distinct clinicopathologic meanings. Hepatology 2011; 53:810.</a></li><li><a href=\"https://www.uptodate.com/contents/histologic-scoring-systems-for-chronic-liver-disease/abstract/22\" class=\"nounderline abstract_t\">Bedossa P, Poitou C, Veyrie N, et al. Histopathological algorithm and scoring system for evaluation of liver lesions in morbidly obese patients. Hepatology 2012; 56:1751.</a></li><li><a href=\"https://www.uptodate.com/contents/histologic-scoring-systems-for-chronic-liver-disease/abstract/23\" class=\"nounderline abstract_t\">Bedossa P, FLIP Pathology Consortium. Utility and appropriateness of the fatty liver inhibition of progression (FLIP) algorithm and steatosis, activity, and fibrosis (SAF) score in the evaluation of biopsies of nonalcoholic fatty liver disease. Hepatology 2014; 60:565.</a></li><li><a href=\"https://www.uptodate.com/contents/histologic-scoring-systems-for-chronic-liver-disease/abstract/24\" class=\"nounderline abstract_t\">Elphick DA, Dube AK, McFarlane E, et al. Spectrum of liver histology in presumed decompensated alcoholic liver disease. Am J Gastroenterol 2007; 102:780.</a></li><li><a href=\"https://www.uptodate.com/contents/histologic-scoring-systems-for-chronic-liver-disease/abstract/25\" class=\"nounderline abstract_t\">Altamirano J, Miquel R, Katoonizadeh A, et al. A histologic scoring system for prognosis of patients with alcoholic hepatitis. Gastroenterology 2014; 146:1231.</a></li><li><a href=\"https://www.uptodate.com/contents/histologic-scoring-systems-for-chronic-liver-disease/abstract/26\" class=\"nounderline abstract_t\">Scheuer P. Primary biliary cirrhosis. Proc R Soc Med 1967; 60:1257.</a></li><li><a href=\"https://www.uptodate.com/contents/histologic-scoring-systems-for-chronic-liver-disease/abstract/27\" class=\"nounderline abstract_t\">Ludwig J, Dickson ER, McDonald GS. Staging of chronic nonsuppurative destructive cholangitis (syndrome of primary biliary cirrhosis). Virchows Arch A Pathol Anat Histol 1978; 379:103.</a></li><li><a href=\"https://www.uptodate.com/contents/histologic-scoring-systems-for-chronic-liver-disease/abstract/28\" class=\"nounderline abstract_t\">Scheuer PJ. Ludwig Symposium on biliary disorders--part II. Pathologic features and evolution of primary biliary cirrhosis and primary sclerosing cholangitis. Mayo Clin Proc 1998; 73:179.</a></li><li><a href=\"https://www.uptodate.com/contents/histologic-scoring-systems-for-chronic-liver-disease/abstract/29\" class=\"nounderline abstract_t\">Nakanuma Y, Zen Y, Harada K, et al. Application of a new histological staging and grading system for primary biliary cirrhosis to liver biopsy specimens: Interobserver agreement. Pathol Int 2010; 60:167.</a></li><li><a href=\"https://www.uptodate.com/contents/histologic-scoring-systems-for-chronic-liver-disease/abstract/30\" class=\"nounderline abstract_t\">de Vries EM, de Krijger M, F&auml;rkkil&auml; M, et al. Validation of the prognostic value of histologic scoring systems in primary sclerosing cholangitis: An international cohort study. Hepatology 2017; 65:907.</a></li><li><a href=\"https://www.uptodate.com/contents/histologic-scoring-systems-for-chronic-liver-disease/abstract/31\" class=\"nounderline abstract_t\">Harada K, Hsu M, Ikeda H, et al. Application and validation of a new histologic staging and grading system for primary biliary cirrhosis. J Clin Gastroenterol 2013; 47:174.</a></li><li><a href=\"https://www.uptodate.com/contents/histologic-scoring-systems-for-chronic-liver-disease/abstract/32\" class=\"nounderline abstract_t\">Portmann B, Zen Y. Inflammatory disease of the bile ducts-cholangiopathies: liver biopsy challenge and clinicopathological correlation. Histopathology 2012; 60:236.</a></li><li><a href=\"https://www.uptodate.com/contents/histologic-scoring-systems-for-chronic-liver-disease/abstract/33\" class=\"nounderline abstract_t\">Ludwig J. Surgical pathology of the syndrome of primary sclerosing cholangitis. Am J Surg Pathol 1989; 13 Suppl 1:43.</a></li><li><a href=\"https://www.uptodate.com/contents/histologic-scoring-systems-for-chronic-liver-disease/abstract/34\" class=\"nounderline abstract_t\">Ludwig J, Barham SS, LaRusso NF, et al. Morphologic features of chronic hepatitis associated with primary sclerosing cholangitis and chronic ulcerative colitis. Hepatology 1981; 1:632.</a></li><li><a href=\"https://www.uptodate.com/contents/histologic-scoring-systems-for-chronic-liver-disease/abstract/35\" class=\"nounderline abstract_t\">LaRusso NF, Wiesner RH, Ludwig J, MacCarty RL. Current concepts. Primary sclerosing cholangitis. N Engl J Med 1984; 310:899.</a></li></ol></div><div id=\"topicVersionRevision\">Topic 3635 Version 16.0</div></div>","outline":"<div id=\"outlineSections\"><h2>Topic Outline</h2><ul id=\"innerOutline\"><li class=\"sr-button\"><a href=\"#H23841634\"><span>SUMMARY</span></a></li><li><a href=\"#H23839870\" id=\"outline-link-H23839870\">INTRODUCTION</a></li><li><a href=\"#H60230083\" id=\"outline-link-H60230083\">LIMITATIONS OF LIVER BIOPSY</a></li><li><a href=\"#H23839876\" id=\"outline-link-H23839876\">CHRONIC HEPATITIS</a><ul><li><a href=\"#H23839896\" id=\"outline-link-H23839896\">Knodell score/histology activity index</a></li><li><a href=\"#H23839890\" id=\"outline-link-H23839890\">METAVIR score</a></li><li><a href=\"#H23839902\" id=\"outline-link-H23839902\">Ishak score (modified Knodell score)</a></li><li><a href=\"#H23839909\" id=\"outline-link-H23839909\">Scheuer system</a></li><li><a href=\"#H23841513\" id=\"outline-link-H23841513\">Batts-Ludwig system (modified Scheuer system)</a></li><li><a href=\"#H23841551\" id=\"outline-link-H23841551\">Laennec staging system</a></li></ul></li><li><a href=\"#H60229745\" id=\"outline-link-H60229745\">DISEASE-SPECIFIC SCORING SYSTEMS</a><ul><li><a href=\"#H2349826112\" id=\"outline-link-H2349826112\">Nonalcoholic fatty liver disease</a><ul><li><a href=\"#H2031372065\" id=\"outline-link-H2031372065\">- Nonalcoholic fatty liver activity score</a></li><li><a href=\"#H47275257\" id=\"outline-link-H47275257\">- Steatosis, activity and fibrosis system</a></li><li><a href=\"#H497091710\" id=\"outline-link-H497091710\">- Fatty liver inhibition and progression</a></li></ul></li><li><a href=\"#H1366946536\" id=\"outline-link-H1366946536\">Alcoholic liver disease and alcoholic hepatitis</a></li><li><a href=\"#H143941062\" id=\"outline-link-H143941062\">Primary biliary cholangitis</a></li><li><a href=\"#H1929080470\" id=\"outline-link-H1929080470\">Primary sclerosing cholangitis</a></li><li><a href=\"#H60230201\" id=\"outline-link-H60230201\">Autoimmune hepatitis</a></li></ul></li><li><a href=\"#H23841634\" id=\"outline-link-H23841634\">SUMMARY</a></li><li><a href=\"#references\">REFERENCES</a></li></ul></div><div><h2>GRAPHICS <a href=\"#\" id=\"viewAllGraphicsLink\">View All</a></h2><div id=\"outlineGraphics\"><ul><li><div id=\"GAST/3635|PIC\" class=\"openRelatedGraphics\"><a href=\"#\" title=\"PICTURES\">PICTURES</a></div><ul><li><a href=\"image.htm?imageKey=GAST/97253\" class=\"graphic graphic_picture\">- Knodell mild inflammation</a></li><li><a href=\"image.htm?imageKey=GAST/97269\" class=\"graphic graphic_picture\">- Knodell moderate inflammation</a></li><li><a href=\"image.htm?imageKey=GAST/98079\" class=\"graphic graphic_picture\">- Knodell marked interface hepatitis</a></li><li><a href=\"image.htm?imageKey=GAST/97270\" class=\"graphic graphic_picture\">- Knodell marked portal inflammation</a></li><li><a href=\"image.htm?imageKey=GAST/97271\" class=\"graphic graphic_picture\">- Knodell multilobular necrosis</a></li><li><a href=\"image.htm?imageKey=GAST/97272\" class=\"graphic graphic_picture\">- METAVIR F1</a></li><li><a href=\"image.htm?imageKey=GAST/97279\" class=\"graphic graphic_picture\">- METAVIR F2</a></li><li><a href=\"image.htm?imageKey=GAST/97281\" class=\"graphic graphic_picture\">- METAVIR F3</a></li><li><a href=\"image.htm?imageKey=GAST/97280\" class=\"graphic graphic_picture\">- METAVIR F4</a></li><li><a href=\"image.htm?imageKey=GAST/97283\" class=\"graphic graphic_picture\">- Ishak score 0</a></li><li><a href=\"image.htm?imageKey=GAST/97296\" class=\"graphic graphic_picture\">- Ishak score 1</a></li><li><a href=\"image.htm?imageKey=GAST/97297\" class=\"graphic graphic_picture\">- Ishak score 2</a></li><li><a href=\"image.htm?imageKey=GAST/97298\" class=\"graphic graphic_picture\">- Ishak score 3</a></li><li><a href=\"image.htm?imageKey=GAST/97299\" class=\"graphic graphic_picture\">- Ishak score 4</a></li><li><a href=\"image.htm?imageKey=GAST/97300\" class=\"graphic graphic_picture\">- Ishak score 5</a></li><li><a href=\"image.htm?imageKey=GAST/97301\" class=\"graphic graphic_picture\">- Ishak score 6</a></li><li><a href=\"image.htm?imageKey=GAST/97282\" class=\"graphic graphic_picture\">- Ishak confluent necrosis</a></li><li><a href=\"image.htm?imageKey=GAST/97302\" class=\"graphic graphic_picture\">- Scheuer stage 1</a></li><li><a href=\"image.htm?imageKey=GAST/97303\" class=\"graphic graphic_picture\">- Scheuer stage 2</a></li><li><a href=\"image.htm?imageKey=GAST/97304\" class=\"graphic graphic_picture\">- Scheuer stage 3</a></li><li><a href=\"image.htm?imageKey=GAST/97305\" class=\"graphic graphic_picture\">- Scheuer stage 4</a></li><li><a href=\"image.htm?imageKey=GAST/97370\" class=\"graphic graphic_picture\">- Batts-ludwig grade 1</a></li><li><a href=\"image.htm?imageKey=GAST/97371\" class=\"graphic graphic_picture\">- Batts-ludwig grade 2</a></li><li><a href=\"image.htm?imageKey=GAST/97373\" class=\"graphic graphic_picture\">- Batts-ludwig grade 3</a></li><li><a href=\"image.htm?imageKey=GAST/97374\" class=\"graphic graphic_picture\">- Batts-ludwig grade 4 interface hepatitis</a></li><li><a href=\"image.htm?imageKey=GAST/97375\" class=\"graphic graphic_picture\">- Batts-ludwig grade 4 confluent necrosis</a></li><li><a href=\"image.htm?imageKey=GAST/97376\" class=\"graphic graphic_picture\">- Batts-ludwig stage 4</a></li><li><a href=\"image.htm?imageKey=GAST/97377\" class=\"graphic graphic_picture\">- Batts-ludwig grade 2 stage 4</a></li><li><a href=\"image.htm?imageKey=GAST/97379\" class=\"graphic graphic_picture\">- Laennec 4A</a></li><li><a href=\"image.htm?imageKey=GAST/97380\" class=\"graphic graphic_picture\">- Laennec 4B</a></li><li><a href=\"image.htm?imageKey=GAST/97381\" class=\"graphic graphic_picture\">- Laennec 4C</a></li><li><a href=\"image.htm?imageKey=GAST/97419\" class=\"graphic graphic_picture\">- NAS score 2</a></li><li><a href=\"image.htm?imageKey=GAST/97420\" class=\"graphic graphic_picture\">- NAS score 6</a></li><li><a href=\"image.htm?imageKey=GAST/97421\" class=\"graphic graphic_picture\">- NAS score 4</a></li><li><a href=\"image.htm?imageKey=GAST/97422\" class=\"graphic graphic_picture\">- ALD expansive fibrosis</a></li><li><a href=\"image.htm?imageKey=GAST/97423\" class=\"graphic graphic_picture\">- ALD bridging fibrosis or cirrhosis</a></li><li><a href=\"image.htm?imageKey=GAST/97454\" class=\"graphic graphic_picture\">- ALD canalicular and hepatocellular cholestasis</a></li><li><a href=\"image.htm?imageKey=GAST/97455\" class=\"graphic graphic_picture\">- ALD megamitochondria</a></li><li><a href=\"image.htm?imageKey=GAST/97457\" class=\"graphic graphic_picture\">- PBC florid duct lesion portal hepatitis</a></li><li><a href=\"image.htm?imageKey=GAST/97458\" class=\"graphic graphic_picture\">- PBC proliferation bile ductules</a></li><li><a href=\"image.htm?imageKey=GAST/97459\" class=\"graphic graphic_picture\">- PBC scarring</a></li><li><a href=\"image.htm?imageKey=GAST/97460\" class=\"graphic graphic_picture\">- PBC with cirrhosis</a></li><li><a href=\"image.htm?imageKey=GAST/97461\" class=\"graphic graphic_picture\">- PSC stage 1 onion-skin fibrosis</a></li><li><a href=\"image.htm?imageKey=GAST/97462\" class=\"graphic graphic_picture\">- PSC stage 1 portal edema bile duct proliferation</a></li><li><a href=\"image.htm?imageKey=GAST/97486\" class=\"graphic graphic_picture\">- PSC stage 2</a></li><li><a href=\"image.htm?imageKey=GAST/97487\" class=\"graphic graphic_picture\">- PSC stage 4 cirrhosis</a></li></ul></li><li><div id=\"GAST/3635|TAB\" class=\"openRelatedGraphics\"><a href=\"#\" title=\"TABLES\">TABLES</a></div><ul><li><a href=\"image.htm?imageKey=GAST/56831\" class=\"graphic graphic_table\">- Knodell score</a></li><li><a href=\"image.htm?imageKey=GAST/98097\" class=\"graphic graphic_table\">- METAVIR score</a></li><li><a href=\"image.htm?imageKey=GAST/98101\" class=\"graphic graphic_table\">- Ishak fibrosis stage</a></li><li><a href=\"image.htm?imageKey=GAST/98099\" class=\"graphic graphic_table\">- Ishak inflammation score</a></li><li><a href=\"image.htm?imageKey=GAST/98102\" class=\"graphic graphic_table\">- Scheuer system hepatitis</a></li><li><a href=\"image.htm?imageKey=GAST/98103\" class=\"graphic graphic_table\">- Batts-Ludwig grading and staging</a></li><li><a href=\"image.htm?imageKey=GAST/98104\" class=\"graphic graphic_table\">- Laennec stage cirrhosis</a></li><li><a href=\"image.htm?imageKey=GAST/98135\" class=\"graphic graphic_table\">- NAFLD activity score</a></li><li><a href=\"image.htm?imageKey=GAST/98136\" class=\"graphic graphic_table\">- Alcoholic hepatitis score</a></li><li><a href=\"image.htm?imageKey=GAST/98137\" class=\"graphic graphic_table\">- Scheuer staging PBC</a></li><li><a href=\"image.htm?imageKey=GAST/98138\" class=\"graphic graphic_table\">- Ludwig staging PBC</a></li><li><a href=\"image.htm?imageKey=GAST/98139\" class=\"graphic graphic_table\">- Histologic score PSC</a></li><li><a href=\"image.htm?imageKey=GAST/98105\" class=\"graphic graphic_table\">- NASH grading and staging</a></li></ul></li></ul></div></div><div><h2>RELATED TOPICS</h2><div id=\"outlineTopics\"><ul><li class=\"plainItem\"><a href=\"topic.htm?path=approach-to-liver-biopsy\" class=\"medical medical_review\">Approach to liver biopsy</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=clinical-manifestations-diagnosis-and-prognosis-of-primary-biliary-cholangitis-primary-biliary-cirrhosis\" class=\"medical medical_review\">Clinical manifestations, diagnosis, and prognosis of primary biliary cholangitis (primary biliary cirrhosis)</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=epidemiology-clinical-features-and-diagnosis-of-nonalcoholic-fatty-liver-disease-in-adults\" class=\"medical medical_review\">Epidemiology, clinical features, and diagnosis of nonalcoholic fatty liver disease in adults</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=interpretation-of-liver-biopsy-specimens\" class=\"medical medical_review\">Interpretation of liver biopsy specimens</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=patient-evaluation-and-selection-for-antiviral-therapy-for-chronic-hepatitis-c-virus-infection\" class=\"medical medical_review\">Patient evaluation and selection for antiviral therapy for chronic hepatitis C virus infection</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=portal-hypertension-in-adults\" class=\"medical medical_review\">Portal hypertension in adults</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=primary-sclerosing-cholangitis-in-adults-clinical-manifestations-and-diagnosis\" class=\"medical medical_review\">Primary sclerosing cholangitis in adults: Clinical manifestations and diagnosis</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=transjugular-liver-biopsy\" class=\"medical medical_review\">Transjugular liver biopsy</a></li></ul></div></div>","javascript":null}